Verlinvest partners with French luxury skincare brand, Cible Skin, to support its unique immuno-cosmetic product development and continued global expansion

Verlinvest partners with French luxury skincare brand, Cible Skin, to support its unique immuno-cosmetic product development and continued global expansion

PARIS, FRANCE, February 8th: Cible Skin has today announced a significant minority investment from Verlinvest, a global, consumer-focused, evergreen investment company. This new investment will enable the pioneering, science-backed skincare brand, Cible Skin, to accelerate growth across geographies including Europe, China and the United States, and supports the development of new products and treatments based on the company’s innovative patented immuno-cosmetic approach.

Cible Skin was founded in 2015 by Pharmaceutical Doctor, Raphaël Aknin, and fellow entrepreneur, Jean Ginefri, with the mission of creating a skincare brand that uses the science of cell immunity and rejuvenation to produce the most potent results. Cible Skin takes a rigorous, research-backed approach to developing high-quality formulations, made in France with the best natural, clean, active ingredients, and offers skincare products including cleansers, serums, and moisturizers. The brand also offers a range of exclusive treatments at its flagship clinic in Paris, La Maison Cible Skin, providing customers with both a luxurious experience and personalized, technical and scientific guidance through their skincare journey.

Cible Skin draws on the expertise of its Scientific Committee, chaired by Dr. Raphaël Aknin, which combines decades of experience in regenerative medicine and immunological science to preserve the health, equilibrium, and beauty of the skin through the innovation of immuno-cosmetics. This clinically proven method boosts the immune system of skin cells to protect, regenerate and repair the skin, with powerful anti-aging, anti-imperfect, antioxidant, and ultra-moisturizing results.

Raphael Thiolon, Managing Director at Verlinvest said: “It is rare in the beauty industry to find a brand like Cible Skin which combines a truly innovative product offering with a science-backed mission and phenomenal results that customers love. Verlinvest is thrilled to be partnering with Raphaël, Jean, and their team to bring Cible Skin’s unique immuno-cosmetic approach to the most discerning skincare consumers around the world.” Cecile Chevallier, Principal at Verlinvest added: “We’re excited to support Cible Skin’s expansion in existing and new markets, and our immediate priority will be to help the business in growing digital, commercial and marketing capabilities, as well as reinforcing its brand, community and organization.”

In less than two years, the brand has gained a cult following amongst its customers, which include top celebrities, with La Maison Cible Skin named “the world’s best beauty clinic for anti-ageing treatments” by Forbes in 2023. Beyond its home market of France, Cible is growing rapidly, achieving multi-million dollars sales in China after launching there in March 2023.

Jean Ginefri, President, and co-founder of Cible Skin said: “With this investment from Verlinvest, Cible Skin will be able to accelerate deployment in our two main markets, France and China, while evaluating potential for further expansion across Europe and America. Cible Skin stands out in the competitive skincare industry through the unrivalled satisfaction and advocacy from our customers. Our goal over the next five years is to become the market leader in luxury, science-backed, cosmetics and we believe Verlinvest is the perfect partner to help us on this path, with their track record of supporting strong international growth while preserving and strengthening the DNA of the brands they back.” Dr. Raphaël Aknin, CEO and co-founder at Cible Skin added: “From the start of this partnership, we have been aligned with Raphael and Cécile on the fundamental role that science, research, and product development plays at Cible Skin. Their support will allow us to achieve our ambition of establishing Cible Skin as a global leader in scientific innovation to better serve the health and beauty of all skin types through best-in-class product efficacy.”

Leveraging decades of experience in building much-loved consumer brands and an international network of offices and advisors, Verlinvest will partner with Cible Skin to support its ambitious growth plan across channels and geographies. Verlinvest’s consumer-focused portfolio includes the likes of Oatly, Tony’s Chocolonely and Remy Cointreau as well as beauty and lifestyle brands Purplle.com and Faceland. Via its venture arm, V3 Ventures, Verlinvest has also backed K-beauty brand Yepoda, personalized supplement company Cuure, skincare creator Revea, and natural deodorant business, Wild.

 

+++ ENDS +++

 

About Cible Skin

Cible Skin was founded in 2015 by Dr. Raphaël Aknin and Jean Ginefri with the mission of creating a luxury cosmetics brand that uses the patented science of cell immunity and rejuvenation to produce the most potent results for customers around the world. After spending five years on research and development, the company launched its first products at the end of 2022 and has grown rapidly since, expanding internationally, most recently into China in March 2023. Cible Skin takes a rigorous, research-backed approach to developing high-quality formulations, made in France with the best natural, clean, active ingredients, and offers both skincare products and exclusive treatments at its flagship clinic in Paris, La Maison Cible Skin.

For more information, visit www.cibleskin.com

 

Read more at Women’s Wear Daily here.

Next article:

Eric Melloul Moves Roles at Verlinvest